402 related articles for article (PubMed ID: 30089719)
41. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
42. Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.
Reckamp KL
J Natl Compr Canc Netw; 2018 May; 16(5S):601-604. PubMed ID: 29784736
[TBL] [Abstract][Full Text] [Related]
43. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
Chuang YC; Huang BY; Chang HW; Yang CN
Sci Rep; 2019 Aug; 9(1):11390. PubMed ID: 31388026
[TBL] [Abstract][Full Text] [Related]
44. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
45. [Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].
Chen R; Jiang C; Tang J; Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):877-887. PubMed ID: 36617474
[TBL] [Abstract][Full Text] [Related]
46. Recent progress in systemic treatment for lung cancer.
Clark JW; Longo DL
Curr Opin Pulm Med; 2018 Jul; 24(4):355-366. PubMed ID: 29697418
[TBL] [Abstract][Full Text] [Related]
47. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
48. Targeted therapy for lung cancer: Beyond EGFR and ALK.
Herrera-Juárez M; Serrano-Gómez C; Bote-de-Cabo H; Paz-Ares L
Cancer; 2023 Jun; 129(12):1803-1820. PubMed ID: 37073562
[TBL] [Abstract][Full Text] [Related]
49. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
50. Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Crystal AS; Shaw AT; Sequist LV; Friboulet L; Niederst MJ; Lockerman EL; Frias RL; Gainor JF; Amzallag A; Greninger P; Lee D; Kalsy A; Gomez-Caraballo M; Elamine L; Howe E; Hur W; Lifshits E; Robinson HE; Katayama R; Faber AC; Awad MM; Ramaswamy S; Mino-Kenudson M; Iafrate AJ; Benes CH; Engelman JA
Science; 2014 Dec; 346(6216):1480-6. PubMed ID: 25394791
[TBL] [Abstract][Full Text] [Related]
51. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Shaw AT
Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
[No Abstract] [Full Text] [Related]
52. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
[TBL] [Abstract][Full Text] [Related]
53. Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.
Remon J; Tabbò F; Jimenez B; Collazo A; de Castro J; Novello S
Clin Transl Oncol; 2020 Sep; 22(9):1425-1429. PubMed ID: 31955355
[TBL] [Abstract][Full Text] [Related]
54.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
55. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.
Chevallier M; Tsantoulis P; Addeo A; Friedlaender A
Cancer Genomics Proteomics; 2020; 17(5):597-603. PubMed ID: 32859638
[TBL] [Abstract][Full Text] [Related]
56. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
57. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V
Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
59. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
60. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.
Hu W; Liu Y; Chen J
Oncotarget; 2017 Apr; 8(15):25046-25054. PubMed ID: 28212572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
